Navigation Links
EYLEA™ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Date:6/28/2011

s and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended March 31, 2011.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
2. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
3. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
4. Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation
5. Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
8. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
9. Reverse NanoJapan: Rice to host 25-30 Japanese students
10. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
11. Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The global market for molecular diagnostics is expected to ... new study by Grand View Research, Inc. Growing demand ... of advanced cancer diagnostic technologies are expected to be ... years. Moreover, the growing global base of geriatric population ... triggering lifestyle habits such as smoking and excessive alcohol ...
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... Adam Chasse, RxTrials, vice president of Corporate Development, ... society, during ceremonies at the University of North Carolina ... Chasse earned a Master of Healthcare Administration degree ... Health at UNC-CH. He has a long and distinguished ...
... 2012 AMRI (NASDAQ: AMRI ) announced ... functions. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ... teams are being combined into one functional sales organization, ... promoted to Vice President, Business Development, North America. This ...
... 2012  Today the Colorado legislature recognized Donor Alliance ... and tissue donation in Colorado. Members of Donor ... community partners accepted the resolution, sponsored by Senator ... Dan Pabon (D-Denver) and Representative Carole Murray (R-Castle ...
Cached Biology Technology:Adam Chasse Inducted Into Delta Omega Public Health Honorary Society 2AMRI Strengthens Business Development and Marketing Groups 2AMRI Strengthens Business Development and Marketing Groups 3Donor Alliance Honored By Colorado Legislature In Observation Of National Donate Life Month 2
(Date:7/31/2014)... Census Bureau, Latinos are the largest minority group in ... Approximately one-third of Latinos are obese and are 1.2 ... Whites. , NYU College of Nursing student researcher ... identify the factors that contribute to this problem by ... on food patterns in Latina women recently published in ...
(Date:7/31/2014)... of the roughly 156,000 gas stations across the ... parts of underground gas storage tankscorrosion that could ... a source of drinking water. In recent years, ... rapidly corroding gas storage tank components such as ... use of gasoline-ethanol blends and the presence of ...
(Date:7/31/2014)... An experimental vaccine protected 100 percent of animal models ... difficile , which causes an intestinal disease that kills ... of print in Infection and Immunity . ... and non-human primates against the purified toxins produced by ... orogastric spore infection, a laboratory model that mimics the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2
... the revolutionary scientific journal that pairs peer-reviewed scholarly text ... submissions are now open for JoVE Behavior, ... section will enable scientists studying behavior to publish cutting ... this scientific field to new levels of productivity, reproducibility ...
... bacteria inside squids use light and chemical signals to control ... be published on April 2 in mBio , the ... Hawaiian bobtail squid, Euprymna scolopes , houses a colony ... using the bacteria at night as an antipredatory camouflage while ...
... April 1, 2013 California sagebrush in the southern ... change than sagebrush populations in the north, according to ... Evolutionary Biology affiliated with the Center for Environmental Biology. ... in Global Change Biology , will assist land ...
Cached Biology News:Symbiotic bacteria program daily rhythms in squid using light and chemicals 2Symbiotic bacteria program daily rhythms in squid using light and chemicals 3Southern California sagebrush better suited to climate change, UCI study finds 2
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
... affinity media for spontaneous ligand immobilization can be ... enzyme, antigen, or receptor to create an affinity ... supports couple ligands via primary amines. Affi-Gel 10 ... from 6.5 to 11; Affi-Gel 15 gel couples ...
Biology Products: